Navigation Links
Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus

RESEARCH TRIANGLE PARK, N.C., March 9 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV).

CMX001 is a broad-spectrum antiviral agent with demonstrated activity against double-stranded DNA (dsDNA) viruses.  The Phase 2 randomized, double-blind, placebo-controlled, dose-escalation study is designed to assess the safety, tolerability and ability of CMX001 to prevent or control CMV infection in stem cell transplant recipients.  CMV, a member of the herpesvirus family of dsDNA viruses, is present in more than two-thirds of the population and typically causes manageable disease in individuals with responsive immune systems.  However, in immunosuppressed and immunocompromised transplant recipients, CMV is a major cause of morbidity and mortality.

"Morbidities and organ loss due to CMV have become a significant medical issue as the frequency of organ transplantation has increased and new immunosuppressive regimes have been introduced," said George Painter, Ph.D., President and Chief Executive Officer.  "CMX001 has demonstrated broad-spectrum activity in preclinical tests against double-stranded DNA viruses - including CMV - and has been well-tolerated to date among volunteers and patients.  We believe that with this combination of potent antiviral activity and tolerability, CMX001 will prove to be a powerful new treatment option for the transplant population and their physicians."

The Phase 2 clinical study is being conducted at approximately 25 leading academic and medical research centers in the United States.  Enrollment in the study is under way and will include approximately 120 patients.  Study participants will receive CMX001 once weekly following stem cell engraftment through post-transplant week 13, and will be monitored for CMV disease and viremia.  Participants will also be monitored for other dsDNA viruses susceptible to CMX001, including adenovirus, BK virus, and Epstein Barr virus.  Safety assessments will be conducted throughout the study.  

About CMX001

CMX001 is a new chemical entity created by applying Chimerix's PIM (Phospholipid Intramembrane Microfluidization) conjugation technology to chemically modify cidofovir, an approved antiviral agent requiring intravenous administration, to produce a highly potent and well-tolerated oral antiviral with broad-spectrum activity.

The enhanced antiviral activity of CMX001 has been characterized in both in vitro and in vivo studies.  In clinical testing to date, CMX001 has shown oral bioavailability in humans and has demonstrated a positive safety profile.  In cell culture assays, CMX001 is significantly more active than cidofovir against numerous dsDNA families of viruses including orthopoxviruses, herpesviruses and multiple adenoviruses.  CMX001 is initially being developed for both commercial and medical preparedness uses.  In addition to the Phase 2 clinical trial in stem cell transplant recipients, Chimerix is conducting a multi-dose Phase 1 clinical trial of CMX001 in transplant recipients with BK viruria, which like CMV can cause serious complications in immunocompromised patients.

About Chimerix

Chimerix is developing antiviral therapeutics to treat life-threatening diseases.  Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza.  The company's lead compound, CMX001, is in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients.  CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release.  CMX157, a late-stage preclinical candidate, is a new chemical entity created by applying Chimerix's PIM (Phospholipid Intramembrane Microfluidization) conjugation technology to chemically modify tenofovir, an approved HIV drug.  CMX157 is being developed as a potential once-weekly nucleoside analogue against HIV infections.  Building on the company's extensive chemical library, Chimerix is also pursuing translational medicine efforts to address malaria, dengue fever and other public health needs.  Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases.  Additional information about Chimerix and its antiviral drug development programs may be found online at

SOURCE Chimerix, Inc.

Back to top



SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
2. Chimerix to Present at Two Upcoming Investor Conferences
3. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
4. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
5. ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS
6. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
9. Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui
10. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
11. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
Post Your Comments:
(Date:10/12/2015)... New York , October 12, 2015 ... (FMI) delivers key insights on the global vital signs monitoring ... Devices Market: Global Industry Analysis and Opportunity Assessment 2015-2025." The ... at a healthy CAGR of 9.5% and 9.2% in terms ... to factors, regarding which FMI offers major insights in detail ...
(Date:10/12/2015)... Oct. 12, 2015 Beginning October 1, 2015 ... Partner, the fastest growing practice management system for therapists, ... easily converts all patient diagnostic codes from the former ... --> --> Therapy Partner has ... mental health practitioners to easily understand the conversion to ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: INDV) ... of Delaware granted the Company,s motion ... Abbreviated New Drug Application (ANDA) No. 205299 to market a ... and naloxone) Sublingual Film (CIII) in the United ... Since August 2013, Indivior has received Paragraph IV certifications ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... October 12, 2015 , ... To help ... its charitable donation to the National Breast Cancer Foundation. The National Breast Cancer ... breast cancer through early detection, education, and support services. , The annual campaign ...
(Date:10/12/2015)... ... October 12, 2015 , ... SQM Group ... a contact channel benchmarking study. Be a part of this insightful ... for improving customer experience, customer journey, contact channel execution and intelligence, workforce optimization, ...
(Date:10/12/2015)... ... ... Holcomb – Kreithen Plastic Surgery and MedSpa, PLLC (“Holcomb – Kreithen”), one of ... Surgery University,” an educational series of mini seminars covering aesthetic and plastic surgery options, ... Saturday, October 24, 2015. , The goal of the event is to provide hands-on ...
(Date:10/12/2015)... ... October 12, 2015 , ... The Asthma and ... Engagement Award by the Patient-Centered Outcomes Research Institute (PCORI) for a new project ... , The project, entitled “Training Patients with Asthma to Understand and Participate in ...
(Date:10/12/2015)... ... October 12, 2015 , ... International law firm Greenberg ... with the U.S. Biomedical Advanced Research and Development Authority (BARDA) reported to be ... ReCell® Autologous Cell Harvesting Device under a U.S. mass casualty preparedness program. ...
Breaking Medicine News(10 mins):